SEC Form 3 · accession 0001171843-18-002117
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ernesto Aycardi-Fonseca
Officer — Chief Medical Officer
Period of report
Mar 19, 2018
Accepted (ET)
Mar 20, 2018 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities are beneficially ownedF1 | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No securities are beneficially ownedF1 | $0.00 | holding | — | — | — | — | — | N/A | — | — | D |
Explanation of responses
- F1Not applicable
Remarks
Exhibit Index: 24.1 Power of Attorney